Navigation Links
VIVUS Announces New Qsymia Offer
Date:3/5/2013

ia, constipation, and dry mouth.

About Qsymia Offer Programs
Save Now! Program - Eligible patients for the Save Now! Program must reside in one of the 50 states and Washington, DC, Puerto Rico, Virgin Islands, or Guam, and be 18 years or older.  This offer is limited to one per patient and applies only to the Qsymia recommended dose of 7.5 mg/46 mg for 30 days.  This offer is available for a limited time and may be modified or discontinued without further notice.  Prescriptions written or filled prior to March 1, 2013 are not eligible for the Save Now! Program.  This offer is not transferable.

This program is not open to patients receiving prescription reimbursement for Qsymia under any federal, state, or government-funded insurance program (for example, Medicaid, Tricare, VA, Department of Defense, Indian Health Service) or where prohibited by law.  Qsymia is categorically excluded from Medicare coverage.  Therefore, if you have Medicare coverage, including under Medicare Part D, and no other additional federal or state healthcare program coverage, you are eligible for this program.

Prescriptions for Qsymia and the Save Now! Program are redeemable by mail order only through CVS/pharmacy, Walgreens, and Walmart Home Delivery Pharmacy.  Qsymia is not available at your local retail pharmacy.  Patients are responsible for any sales tax.  You may not submit a claim for the amounts covered by the offer for payment to any third-party payers, including a flexible spending account, a Health Savings Account (HSA), or a Health Reimbursement Account (HRA).

Acceptance of this offer must be consistent with the terms of any drug benefit provided by your health insurer, health plan, or private third-party payer, and you agree to report acceptance of this offer to your health insurer, health plan
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sequenom Announces Participation At The Barclays Global Healthcare Conference
2. Noven Announces FDA Advisory Committee Vote on Investigational Low-Dose Mesylate Salt of Paroxetine (LDMP) for Vasomotor Symptoms Associated with Menopause
3. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
4. SI-BONE, Inc. Announces Spring Society Meeting Attendance
5. Relmada Therapeutics Announces LevoCap ER Development Progress
6. Boehringer Ingelheim Announces Interim Results Evaluating Virologic Response Rates in HCV/HIV Co-Infected Patients Treated with Faldaprevir
7. Evofem Announces Strategic Alliance with WomanCare Global
8. DMH International Announces Agreement with MyDICOM and ChangZhou Wealth Information & Technology Co. Ltd
9. Hill-Rom Announces Second Quarter 2013 Dividend
10. NeuroDerm Announces Positive Results of a Phase I Study of ND0612 for the Treatment of Parkinsons Disease
11. Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Affymax, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... KENNESAW, Ga. and RALEIGH, ... Clinical Trial Marketing Communications, LLC (CTMC), and Integrated ... in patient recruitment and retention for clinical trials ... called Integrated Clinical Trial Marketing Services (i-CTMS). i-CTMS ... and retention services to pharmaceutical, biotechnology and medical ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... of the "Inferior Vena Cava (IVC) Filters - ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... is projected to reach US$435 million by 2016. The ... 39% (2015) of the global value while ...
(Date:12/15/2014)... BRIDGEWATER, N.J. , Dec. 15, 2014   ... SAN and NYSE: SNY) are collaborating with nationally-recognized patient ... Counts , an awareness program that will gauge how ... risks associated with high LDL-C (bad cholesterol).  American adults ... to take a brief poll and answer a few ...
Breaking Medicine Technology:Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 2Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 3Inferior Vena Cava (IVC) Filters - Global Trends, Estimates and Forecasts, 2012-2018 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 2Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 3Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 4Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 5Have You Been Counted? Regeneron and Sanofi US Join Forces with Leading Cardiovascular Organizations to Raise Awareness of Cholesterol 6
... begin Phase IIb study in the first half of ... (Nasdaq: ALSE ), announced today that it has,concluded ... in acute,spinal cord injury (SCI). A total of 48 ... States and Canada. We expect to release periodic,updates of ...
... PHILLIPSBURG, N.J., Jan. 7 Celldex Therapeutics,announced today ... has,granted Fast Track designation to Celldex,s CDX-110 for ... is the most common,and aggressive form of primary ... current therapy. CDX-110 is an immunotherapy that targets,the ...
Cached Medicine Technology:Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 2Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 3Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 4Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury 5Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 3Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 4Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 5
(Date:12/17/2014)... 17, 2014 In its comprehensive analysis ... its Argus Claim Review division have recently identified out-of-network ... common ways savings are achieved on behalf of employer-clients. ... of dollars in savings to Argus each year, with ... As explained by Tom Doney, Cypress president and CEO, ...
(Date:12/17/2014)... December 17, 2014 Now in its ... the best of the best in senior living and ... only given to communities and agencies that have received ... site. Of the nearly 100,000 providers currently listed on ... of the SeniorAdvisor.com Best of 2015 Awards are located ...
(Date:12/17/2014)... 15, 2014 (HealthDay News) -- As gas prices rose ... a new study suggests. In times of gas ... those riders are inexperienced, the researchers explained. They ... which has the highest number of motorcycle registrations in ... motorcyclist deaths. The analysis revealed a strong association ...
(Date:12/17/2014)... Expectant parents should leave prenatal picture-taking to medical professionals, ... of ultrasound imaging and heartbeat monitors to get "keepsake" ... warns. "Although there is a lack of ... heartbeat monitors, prudent use of these devices by trained ... biomedical engineer, said in an agency news release. ...
(Date:12/17/2014)... -- Greater participation in music classes may benefit children,s ... kids in the nonprofit Harmony Project, which provides music ... Over two years, children who actively participated in ... processes speech and reading, compared to those with lower ... participation in music classes occurred in the same areas ...
Breaking Medicine News(10 mins):Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2Health News:Music Classes Boost Language Skills, Study Says 2
... (May 1, 2011) -- A drug commonly used to treat ... according to a study published in the May issue of ... kinase inhibitor, blocks the action of mammalian target of rapamycin ... tumor growth. It,s used to treat advanced renal cell carcinoma. ...
... ATHENS, Ohio (April 30, 2011) The Osteopathic Heritage Foundations, ... represents the largest private donation ever given to a college ... to address some of the most pressing health care issues ... of primary care physicians and the diabetes epidemic. The ...
... HealthDay Reporter , FRIDAY, April 29 (HealthDay News) -- ... debate on whether or not American women should begin regular ... the annual meeting of the American Society of Breast ... to 49 with mammograms detected smaller breast cancers, with less ...
... in the emergency department (ED) complaining primarily of lower ... tested for sexually transmitted infections (STIs), according to the ... 30, at the Pediatric Academic Societies (PAS) annual meeting ... when adolescents seek treatment for symptoms suggestive of an ...
... from elevated anxiety. Patient discomfort may cause poor ... Anxiolytic medications are currently used to reduce this ... non-invasive alternative treatment with fewer adverse effects, according to ... Ray Society,s annual meeting. The project was conceived ...
... April 29 (HealthDay News) -- Multiple pregnancies may increase ... plaque in the arteries, suggests new research in mice. ... studied mice late in gestation in either their first ... severe glucose intolerance and excess fat tissue, while those ...
Cached Medicine News:Health News:Renal cancer drug temsirolimus shows promise against mesothelioma 2Health News:Record funding award given to Ohio University College of Osteopathic Medicine 2Health News:Record funding award given to Ohio University College of Osteopathic Medicine 3Health News:Record funding award given to Ohio University College of Osteopathic Medicine 4Health News:Record funding award given to Ohio University College of Osteopathic Medicine 5Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 2Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 3Health News:Mammograms Can Save Lives of Women in Their 40s: Studies 4Health News:EDs should be aware of sexually transmitted infection risk in patients 2Health News:Animal-assisted therapy decreases patient anxiety in pre-MRI setting, study suggests 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: